Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Next Wave Ventures in connection with the acquisition of Rexam Plc’s Petainer operations
Mandate

Vinge advises Next Wave Ventures in connection with the acquisition of Rexam Plc’s Petainer operations

November 23, 2009

Vinge has advised Next Wave Ventures in the acquisition by Next Waves and WHEB Ventures of Rexam Plc’s Petainer operations in Sweden, the Czech Republic and Germany for approximately SEK 190,000,000 (GBP 16,000,000).

Rexam’s Petainer operations manufacture PET beverage containers. The facilities in Lidköping and the Czech Republic have 250 employees and a combined turnover of SEK 700 million. These facilities primarily supply PET bottles to the Nordic and German markets. Next Wave is an English private equity and venture capital firm focused on investing in UK and European small cap companies and WHEB invests in companies focusing on environmentally friendly technology and sustainable solutions.

The Vinge team advising Next Wave consisted of partner Jesper Ottergren together with, among others, associates Anna Bjering, Magnus Bigner, Anna Bergstrand, Susanne Samuelsson and Ida Christensson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025